Braud, A C <br/><br/>
Overexpression of erb B2 remains a major risk factor in non-metastatic breast cancers treated with high-dose alkylating agents and autologous stem cell transplantation.  [electronic resource] 

 -  Bone marrow transplantation  May 2002 
 - 753-7 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0268-3369 
<br/><br/><label>Standard No.: </label>10.1038/sj.bmt.1703540  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Alkylating--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Biomarkers, Tumor--analysis<br/>Breast Neoplasms--diagnosis<br/>Disease-Free Survival<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Neoplasm Proteins--metabolism<br/>Peripheral Blood Stem Cell Transplantation--methods<br/>Prognosis<br/>Receptor, ErbB-2--metabolism<br/>Risk Factors<br/>Survival Rate<br/>Transplantation, Autologous--methods